Navigation Links
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
Date:11/2/2007

, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping PEGASYS therapy (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

Use with Ribavirin. Ribavirin, including COPEGUS, may cause birth defects and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with ribavirin therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

PEGASYS is contraindicated in patients with hypersensitivity to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during treatment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic CHC patients coinfected with HIV before or during treatment. PEGASYS is also contraindicated in neonates and infants because it contains benzyl alcohol. Benzyl alcohol is associated with an increased incidence of neurological and other complications in neonates and infants, which are sometimes fatal. PEGASYS and COPEGUS therapy is additionally contraindicated in patients with a hypersensitivity to COPEGUS or any of its components, in women who are pregnant, men whose female partners are pregnant, and patients with hemoglobinopathies (eg, thalassemia major, sickle-cell anemia).

COPEGUS THERAPY SHOULD NOT BE STARTED UNLESS A REPORT OF A NEGATIVE PREGNANCY
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... /PRNewswire-iReach/ -- June 28 th , 2014 – Oncolab, the ... AMAS cancer test, is making its AACC debut (booth #4051) ... which is a serum-based in vitro immunoassay, has been run ... tool in the fight against cancer recurrence. Photo ... 17 million cancer survivors in the US alone, the race ...
(Date:7/28/2014)... , July 28, 2014  Air Products (NYSE: ... of medical oxygen is vital to any healthcare facility. ... that not only improve the efficiency of its oxygen ... will highlight these systems—including systems for emergency oxygen ... loss—from August 4-5 at the 51 st ...
(Date:7/28/2014)... 28, 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... that leads to inflammation and pain in the human body,s ... addition, it causes inflammation of the tissues that surround the ... symptoms of RA begin slowly, usually just mild pain around ...
Breaking Medicine Technology:Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3Global Rheumatoid Arthritis Drugs Market 2014-2018 2
(Date:7/28/2014)... York, NY (PRWEB) July 28, 2014 ... filed on behalf of individuals who were allegedly ... Replacement System continue to move forward in U.S. District ... According to an Order issued on July 18, 2014, ... a motion filed by the Plaintiffs’ Steering Committee that ...
(Date:7/28/2014)... Braintree, Massachusetts (PRWEB) July 28, 2014 ... the Summit Provider Exchange technology solution ... office integration efforts and support collaboration with their ... 242 bed acute-care medical center located in New ... 800,000 seasonal visitors with a variety of inpatient ...
(Date:7/28/2014)... chronic medical conditions people have at retirement age, the ... claims. Since nearly four in five older ... Bloomberg School of Public Health in Baltimore said the ... are slowing in the United States. "Living with ... heart failure is now the norm and not the ...
(Date:7/28/2014)... Steven Reinberg HealthDay Reporter ... who have dementia and heart rhythm irregularities are more likely ... has found. In fact, the study of more than ... 80 percent more likely to get a pacemaker than those ... this study is why folks with dementia are so much ...
(Date:7/28/2014)... July 28, 2014 Parker Waichman LLP, a ... to ensure that the heroes of 9/11 are never forgotten, ... announced an important deadline. According to a VCF message ... a covered cancer on or before October 12, 2012 must ... First responders and others who were allegedly injured by the ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3
... June 18 Roxane Laboratories, Inc.,announced today ... Application (ANDA),for Ramipril Capsules, 1.25mg, 2.5mg, 5mg ... Administration. The 1.25mg, 2.5mg, 5mg and 10mg ... Roxane Laboratories Ramipril,Capsules are available for immediate ...
... cancer who had abundant vitamin D in their blood were ... who were deficient in the vitamin, according to a new ... of the study -- the first to examine the effect ... research, but it is too early to recommend supplements as ...
... a human patient,s cloned infection-fighting T cells as the sole ... A team led by Cassian Yee, M.D., an associate member ... Center, reports these findings in the June 19 issue of ... and colleagues removed CD4+ T cells, a type of white ...
... Authority continues monitoring and evaluating wrong-site surgeries,with ... wrong-site surgery,update, HARRISBURG, Pa., June 18 ... "National Time Out Day," which is a,national ... time out" before every,operation to confirm correct ...
... DENVER, June 18 Air Methods Corporation,(Nasdaq: ... in the,world, announced today that Chief Executive Officer ... present at the Jefferies 2nd Annual,Healthcare Conference in ... at 11:15,a.m. ET., Interested parties can listen ...
... in Indiana to propose awareness-raising ... legislation in 2009., ... of July as Indiana Safe Haven Month and the,National Safe Haven ... for babies who were adopted thanks to legislation,passed overwhelmingly in the ...
Cached Medicine News:Health News:Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules 2Health News:Study links vitamin D to colon cancer survival 2Health News:Patient's own infection-fighting T cells put late-stage melanoma into long-term remission 2Health News:Patient Safety Authority Supports 'National Time Out Day' 2Health News:Governor and Lt. Governor Celebrate Eight Years of Safe Haven Babies 2
... Nylon Finger Traps for optimum patient comfort. The ... skin with a firm grip. ISI Nylon Finger ... system when used with the ISI Digi Grip ... Finger Traps are available in non-sterile packs and ...
... The ApexPro FH ... spread spectrum wireless infrastructure ... WMTS for dependable communication ... FH offers scalability of ...
Spacelabs offers an approach that allows your telemetry and step-down units to configure systems to meet their telemetry requirements. Our modular telemetry system data are integrated into the depart...
ISI Alumi-Hand is the safe, sterile, ready-to-use ,surgical hand immobilizer....
Medicine Products: